Novartis shares rise as Remibrutinib MS trials succeed, while CAR-T study pause and deaths raise saf

Detailed price information for Novartis Ag ADR (NVS-N) from The Globe and Mail including charting and trades.

Korean biotechnology company Alteogen Inc. said Wednesday that it signed an option and licensing agreement with Novartis AG worth up to 4.4 trillio...

Novartis shares jump 5.3% as Remibrutinib beats Aubagio in MS trials, but safety halt in Rap-Cel stu

Novartis has suspended eight clinical trials of its experimental CAR-T therapy rap-cel after three patient deaths involving severe immune reactions.…

Novartis AG stocks have been trading up by 6.13 percent after positive trial data strengthened confidence in its drug pipeline. Key Takeaways For NVS Traders Novartis reported Q2 adjusted sales of DKK 78.49B with 7% constant-currency growth and adjusted operating profit up 11% at constant exchange

Positive late-stage trial results for a key Novartis AG drug lifted investor confidence, and stocks have been trading up by 5.85 percent. Key Takeaways Q2 adjusted sales rose to DKK 78.49B, up 7% at constant currencies, with adjusted operating profit climbing 11% to DKK 33.39B, showing solid operating momentum at Novartis AG. The FDA granted…

Novartis AG stocks have been trading up by 5.85 percent amid strong investor optimism over its recent breakthrough drug news. Key Takeaways For NVS Traders Q2 adjusted sales reached DKK 78.49B, up 7% in constant currency, while adjusted operating profit climbed 11% to DKK 33.39B, showing strong